Successful treatment with clozapine in a patient with neuroleptic-induced acute laryngeal dystonia

Lanzaro, M.; Petrone, R; d’Ambrosio, Adrien

doi:10.1016/s0924-9338(01)00576-4

Cited by 8 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[50][51][52][53] Clozapine, a GABA receptor antagonist, has also reportedly reduced symptoms of oromandibular dystonia and laryngeal dystonia in single case reports. 54,55 Because of the limited randomized, controlled trials of the effectiveness of GABA modifying drugs in the treatment of focal dystonia and the inconsistent and unpredictable outcomes, GABA modifying drugs have not been adopted into routine clinical practice. [56][57][58] Neuroimaging A complimentary tool to TMS in the investigation of the neurophysiology in dystonia is neuroimaging.…”

Section: Discussionmentioning

confidence: 99%

Cortical Silent Period Reveals Differences Between Adductor Spasmodic Dysphonia and Muscle Tension Dysphonia

Samargia

Schmidt

Kimberley

2015

Neurorehabil Neural Repair

View full text Add to dashboard Cite

Background The pathophysiology of adductor spasmodic dysphonia (AdSD), like other focal dystonias, is largely unknown. Objective The purposes of this study were to determine 1) cortical excitability differences between AdSD, muscle tension dysphonia (MTD) and healthy controls 2) distribution of potential differences in cranial or skeletal muscle, and 3) if cortical excitability measures assist in the differential diagnosis of AdSD and MTD. Methods 10 participants with adductor spasmodic dysphonia, 8 with muscle tension dysphonia and 10 healthy controls received single and paired pulse transcranial magnetic stimulation (TMS) to the primary motor cortex contralateral to tested muscles, first dorsal interosseus (FDI) and masseter. We tested the hypothesis that cortical excitability measures in AdSD would be significantly different than in MTD and healthy. In addition, we hypothesized there would be a correlation between cortical excitability measures and clinical voice severity in AdSD. Results Cortical silent period (CSP) duration in masseter and FDI was significantly shorter in AdSD than MTD and healthy controls. Other measures failed to demonstrate differences. Conclusion There are differences in cortical excitability between AdSD, MTD and healthy controls. These differences in the cortical measure of both the FDI and masseter muscles in AdSD suggest widespread dysfunction of the GABAB mechanism may be a pathophysiologic feature of AdSD, similar to other forms of focal dystonia. Further exploration of the use of TMS to assist in the differential diagnosis of AdSD and MTD is warranted.

show abstract

Section: Discussionmentioning

confidence: 99%

Cortical Silent Period Reveals Differences Between Adductor Spasmodic Dysphonia and Muscle Tension Dysphonia

Samargia

Schmidt

Kimberley

2015

Neurorehabil Neural Repair

View full text Add to dashboard Cite

show abstract

“…This shorter CSP suggests less cortical inhibition in unaffected muscles, indicating a more global, widespread GABA dysfunction. In a case of neuroleptic‐induced symptoms of secondary SD, clozapine, a GABA antagonist, reduced symptoms following administration 40 . However, reports of GABA‐modifying drugs benefiting idiopathic SD remain limited to a select few cases.…”

Section: Methodsmentioning

confidence: 99%

“…In a case of neuroleptic-induced symptoms of secondary SD, clozapine, a GABA antagonist, reduced symptoms following administration. 40 However, reports of GABA-modifying drugs benefiting idiopathic SD remain limited to a select few cases.…”

Section: Neurologic Factorsmentioning

confidence: 99%

Spasmodic Dysphonia: A Review. Part 1: Pathogenic Factors

Hintze

Ludlow

Bansberg

et al. 2017

Otolaryngol.--head neck surg.

View full text Add to dashboard Cite

Objective The purpose of this review is to describe the recent advances in identifying possible factors involved in the pathogenesis of spasmodic dysphonia. Spasmodic dysphonia is a task-specific focal laryngeal dystonia characterized by irregular and uncontrolled voice breaks. Pathogenesis of the disorder is poorly understood. Data Sources PubMed, Google Scholar, and Cochrane Library. Review Methods The data sources were searched using the following search terms: ( spasmodic dysphonia or laryngeal dystonia) and ( etiology, aetiology, diagnosis, pathogenesis, or pathophysiology). Conclusions Several potential etiological factors have been proposed by epidemiological, genetic, and neuropathological studies. Spasmodic dysphonia is a rare disorder primarily affecting females beginning in their 40s. Vocal tremor co-occurs in 30% to 60%. Large cohort studies identified risk factors such as a family history of neurological disorders including dystonia and tremor, recent viral illness, and heavy voice use. As none are rare events, a complex interactive process may contribute to pathogenesis in a small proportion of those at risk. Consequences to pathogenesis are neurological processes found in spasmodic dysphonia: loss of cortical inhibition, sensory processing disturbances, and neuroanatomical and physiological differences in the laryngeal motor control system. Implications for Practice Diagnosis of spasmodic dysphonia usually includes speech and laryngoscopic assessment. However, as diagnosis is sometimes problematic, measurement of neurophysiological abnormalities may contribute useful adjuncts for the diagnosis of spasmodic dysphonia in the future.

show abstract

Current Awareness

2001

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

In order to keep subscribers up‐to‐date with the latest developments in their field, John Wiley & Sons are providing a current awareness service in each issue of the journal. The bibliography contains newly published material in the field of pharmacoepidemiology and drug safety. Each bibliography is divided into 19 sections: 1 Books, Reviews & Symposia; 2 General; 3 Anti‐infective Agents; 4 Cardiovascular System Agents; 5 CNS Depressive Agents; 6 Non‐steroidal Anti‐inflammatory Agents; 7 CNS Agents; 8 Anti‐neoplastic Agents; 9 Haematological Agents; 10 Neuroregulator‐Blocking Agents; 11 Dermatological Agents; 12 Immunosuppressive Agents; 13 Autonomic Agents; 14 Respiratory System Agents; 15 Neuromuscular Agents; 16 Reproductive System Agents; 17 Gastrointestinal System Agents; 18 Anti‐inflammatory Agents ‐ Steroidal; 19 Others. Within each section, articles are listed in alphabetical order with respect to author. If, in the preceding period, no publications are located relevant to any one of these headings, that section will be omitted.

show abstract

Successful treatment with clozapine in a patient with neuroleptic-induced acute laryngeal dystonia

Cited by 8 publications

References 5 publications

Cortical Silent Period Reveals Differences Between Adductor Spasmodic Dysphonia and Muscle Tension Dysphonia

Cortical Silent Period Reveals Differences Between Adductor Spasmodic Dysphonia and Muscle Tension Dysphonia

Spasmodic Dysphonia: A Review. Part 1: Pathogenic Factors

Current Awareness

Contact Info

Product

Resources

About